Co-Inventors
Schnell, Matthias
Abreu Mota, Tiago
Therapeutic Areas
Respiratory
Rare/Neglected Diseases
Infectious Disease
Research Products
Research Equipment
Antibodies
Animal Models
The bivalent rabies and Lassa virus vaccine represents a significant advancement in vaccine development, offering dual protection against two deadly viral diseases. By combining antigens from both viruses, this vaccine has shown promising immunogenicity in mice and efficacy in reducing viral yield in a relevant animal model. Developed through collaboration with experts from Thomas Jefferson University, including Matthias Schnell and Tiago Abreu Mota, this vaccine has the potential to address major global health challenges posed by Lassa fever and rabies, particularly in endemic regions. As the technology is in the Discovery stage, further research is underway to evaluate its safety and efficacy, with plans for future publication and potential advancement to clinical trials.
Commercial Applications
The bivalent rabies and Lassa virus vaccine has the potential for diverse applications in public health. Primarily, it could be used in regions where both Lassa fever and rabies are endemic, offering a comprehensive approach to disease prevention. Additionally, the vaccine may find utility in travel medicine, providing travelers to endemic areas with protection against these diseases. Furthermore, the vaccine's bivalent nature opens up possibilities for inclusion in routine immunization schedules, particularly in areas where these diseases pose a significant health burden. Lastly, the technology behind this vaccine could serve as a platform for the development of other bivalent or multivalent vaccines, leveraging the success and knowledge gained from this innovative approach.
Competitive Advantages
The bivalent rabies and Lassa virus vaccine holds several key competitive advantages over existing vaccines. Firstly, its dual-action design offers simultaneous protection against two severe viral diseases, providing a comprehensive solution in regions where both diseases are prevalent. Secondly, the vaccine's demonstrated immunogenicity in mice and efficacy in animal models suggest a strong potential for effectiveness in humans. Thirdly, the collaboration with experts from Thomas Jefferson University ensures that the vaccine benefits from cutting-edge research and expertise in virology and vaccine development. Additionally, the vaccine's development at the Discovery stage indicates the potential for further optimization and enhancement, positioning it as a frontrunner in the quest for a safe and effective bivalent vaccine against rabies and Lassa virus.
